Genomic Variant Interpretation for Drug Target Discovery
Analyze genomic variants to identify drug targets with regulatory-ready assessments
What You Can Do
You can translate raw variant catalogs and NGS data into actionable target hypotheses by synthesizing variant effect predictions, population frequency metrics, disease association evidence, and protein interaction networks. This skill automates the connection between molecular findings and clinical relevance, producing comprehensive variant assessments that justify target selection across pharmaceutical development stages and support regulatory submissions.
Features
Evaluates missense, loss-of-function, and regulatory impact consequences using computational annotations
Analyzes gnomAD frequencies, internal cohort data, and allele balance to establish variant significance
Integrates GWAS catalog evidence and literature context to link variants to therapeutic indications
Maps variants to protein interactions and biological pathways relevant to drug mechanism
Scores target tractability including existing inhibitors, biomarker potential, and therapeutic feasibility
Generates 21 CFR Part 11-compliant reports with full data traceability for IND submissions
Creates variant assessment summaries tailored for medicinal chemistry, clinical ops, and leadership stakeholders
Example Output
Example 1: GWAS Variant Prioritization Report
Variant: rs12345678 (BRCA1 p.Arg1699Gln)
- Effect Prediction: Missense variant; in silico tools predict deleterious impact (SIFT score 0.02, PolyPhen-2 probably damaging)
- Population Data: Frequency 0.0012 in gnomAD; enriched 3.2-fold in breast cancer cohort (p=1.2e-8)
- Disease Association: 47 literature citations linking BRCA1 loss-of-function to HER2+ breast cancer; 15 active clinical trials targeting BRCA1 pathway
- Druggability Score: 8.2/10 (high target tractability); 12 existing PARP inhibitors; potential companion diagnostic biomarker
- Regulatory Ready: ✓ Validated assay; ✓ Literature evidence; ✓ Mechanism rationale
Example 2: RNA-seq Rare Variant Assessment
Variant: Novel insertion NM_001234.5 c.2456_2457insAGA (EGFR exon 19)
- Functional Impact: Frameshift leading to premature stop codon (p.Ala819fs)
- Expression Context: Detected in 18/200 patient samples with lung adenocarcinoma; absent in 1000 controls
- Pathway Relevance: Complete loss of kinase domain; predicted non-functional EGFR
- Clinical Translation: Matches erlotinib-resistant phenotype; candidate for next-gen TKI screening
- Regulatory Flag: De novo variant; requires independent validation and functional confirmation for IND roadmap
What's Included
- SKILL.md: Complete variant interpretation workflow with standard operating procedures
- Variant Assessment Template: Structured report framework for documenting variant classification, evidence synthesis, and regulatory justification
- Functional Annotation Checklist: Step-by-step guide for evaluating effect predictions, population metrics, and disease associations
- Druggability Scoring Framework: Quantitative assessment criteria and weighting for target tractability evaluation
- Regulatory Compliance Worksheet: 21 CFR Part 11 requirements checklist and data traceability documentation table
Who It's For
- Bioinformatics Scientists — Interpreting NGS data and variant catalogs for drug target discovery and validation
- Computational Biologists — Synthesizing multi-source genomic evidence to support target nomination and IND progression
- Clinical Development Scientists — Building regulatory-ready variant assessment packages for investigator meetings and submissions
- Genomics Project Managers — Coordinating variant interpretation deliverables across preclinical and clinical teams
- Research Scientists (Medicinal Chemistry) — Evaluating genetic targets and understanding molecular basis for compound screening
Best For
- GWAS data interpretation and rare variant prioritization for therapeutic target discovery
- WES/WGS variant calling output synthesis and cross-sample variant assessment
- Regulatory submission preparation requiring variant classification and disease association evidence
- Target tractability evaluation and druggability scoring for lead optimization decisions
- Cross-functional reporting on variant findings to non-bioinformatics stakeholders (medicinal chemistry, clinical operations)
You might also like
This skill systematically analyzes your product designs to identify manufacturability issues early, saving costly revisions and manufacturing delays. It evaluates geometry, material selection, tolerances, assembly feasibility, and production process constraints. You get actionable feedback on cost drivers, process risks, and design optimizations before committing to production.
by kody-w
You can submit tool designs—drawings, specifications, or descriptions—and Claude will evaluate manufacturability constraints, identify potential failure modes using structured frameworks, and recommend cost-reduction opportunities. You'll receive a prioritized report covering structural analysis, production feasibility, material efficiency, and design trade-offs.
by kody-w
You can automate the validation of clinical trial data against protocol specifications, identify discrepancies including missing values, out-of-range results, protocol violations, and CRF inconsistencies. The skill generates audit-ready query documentation, categorizes anomalies by severity and type, resolves root causes systematically, and produces FDA inspection-ready reports that trace every data decision and corrective action for CDISC and regulatory submission.
by kody-wThis skill interprets your FEA simulation results and extracts actionable design improvements. You can pinpoint stress concentrations, validate designs against safety factors and material limits, and receive specific geometry recommendations to reduce weight or improve performance. By automating FEA post-processing, you compress design iteration cycles and make engineering decisions faster.
by kody-w
You can validate eCRF and paper CRF datasets against protocol-defined rules, automatically identify data discrepancies (missing fields, out-of-range values, date inconsistencies), generate structured Data Query Forms (DQFs) for site clarification, track resolution status, and create audit-ready compliance documentation that meets FDA 21 CFR Part 11 and GCP requirements. This workflow reduces manual validation time while ensuring 100% traceability and regulatory readiness for inspections.
by kody-w
Get comprehensive PCB design analysis covering power delivery networks, signal integrity, thermal management, and manufacturing constraints. Claude identifies potential issues early and provides specific, actionable optimization recommendations to reduce cost, improve reliability, and accelerate time-to-market. Suitable for designs from initial concept through production-ready layouts.
by kody-w
You consolidate parallel data streams from preclinical toxicology studies (clinical pathology, histopathology, body weight changes, organ weights, clinical observations, mortality) into coherent regulatory-compliant narratives. This skill synthesizes findings across 6–12 endpoints simultaneously, identifies NOAEL/LOAEL with biological justification, determines safety margins, interprets species-specific or sex-specific signals, and produces Results & Discussion sections that satisfy FDA/EMA reviewers while supporting appropriate dosing decisions for IND-enabling studies.
by kody-w
You can analyze equipment sensors, operational logs, and historical maintenance data to predict failures weeks in advance. Claude generates actionable maintenance schedules, identifies high-risk assets, and calculates the financial impact of preventive vs. reactive maintenance. This skill transforms raw operational data into strategic maintenance decisions that minimize downtime and extend asset life.
by kody-w